Figure 1
Figure 1. Distribution of expression of FLI1 in AML. (A) Distribution of expression of FLI1 based on BM versus PB. (B) Distribution of expression of FLI1 based on disease status: the expression between 47 paired diagnosis and relapse specimens is shown. The expression ranges of normal CD34+ cells are shown beside the y-axis. (C) Histogram of expression in all AML patients relative to normal CD34+ cells. FLI1 levels were above normal CD34+ cells in 31.8% of AML patients and below normal in 4.8%. Expression is shown in log 2 scale. The rug immediately above the x-axis shows the APL patients. Three different “normal controls” are shown as rugs below the x-axis, including G-CSF–primed CD34+ cells (top), normal CD34+ cells (middle), and PBLs (bottom).

Distribution of expression of FLI1 in AML. (A) Distribution of expression of FLI1 based on BM versus PB. (B) Distribution of expression of FLI1 based on disease status: the expression between 47 paired diagnosis and relapse specimens is shown. The expression ranges of normal CD34+ cells are shown beside the y-axis. (C) Histogram of expression in all AML patients relative to normal CD34+ cells. FLI1 levels were above normal CD34+ cells in 31.8% of AML patients and below normal in 4.8%. Expression is shown in log 2 scale. The rug immediately above the x-axis shows the APL patients. Three different “normal controls” are shown as rugs below the x-axis, including G-CSF–primed CD34+ cells (top), normal CD34+ cells (middle), and PBLs (bottom).

Close Modal

or Create an Account

Close Modal
Close Modal